$Bob's and Jbem's Bitchin' Bios

[LasNubes]

m;
The MultiStem treatment group had a lower rate of life threatening adverse events and death (p=0.04), and also exhibited lower rates of pulmonary events (p=0.08) and infections. The MultiStem treated group also had a significantly lower level of circulating CD-3+ T-cells at two days following dosing (p<0.01), suggesting a reduction in the inflammatory response post-stroke, consistent with the therapeutic hypothesis.
As noted above, post-hoc analyses show that earlier MultiStem administration appears to provide substantial benefit, as evident in the following